Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show

Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show
Results from the GO-COLITIS clinical trial (NCT02092285) confirm that the long-term effects of Janssen Pharmaceutical’s Simponi (golimumab) were maintained in patients with ulcerative colitis (UC), according to MSD, sponsor of the study. The United Kingdom (UK)-based study confirmed the effectiveness of the drug in inducing and maintaining clinical response during the 66 weeks of treatment since the beginning of the trial.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *